drugset / Trial / NCT05113693
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
RandomizedCrossoverOpen-labelTreatment
Summary
Objective \- Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
Timeline
- Start
- 2021-11-25
- Primary completion
- 2021-12-06
- Completion
- 2021-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-393 | Unknown | 0.25 mg | Oral |
| Subject | CKD-393 | Unknown | 50 mg | Oral |
| Subject | CKD-393 | Unknown | 750 mg | Oral |
| Subject | D759 | Unknown | — | Oral |
| Subject | H053 | Unknown | — | Oral |
| Subject | Lobeglitazone | Small molecule | — | Oral |